ERBB2 and breast cancer: DNA sequencing was applied to detect somatic mutations and copy number alterations in key genes, including ERBB2(HER2) and BRCA1/2, and to assess the proportion of patients in the present study that harbored somatic alterations that may be clinically actionable in the future, as defined by ongoing or concluded clinical breast cancer trials.